CQS Cayman’s Tempest Therapeutics TPST Stock Holding History

CQS Cayman’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-234	Closed	-$1.05M	–	122
2016 Q4	$1.05M	Hold	234	–	–	0.08%	95
2016 Q3	$4.9M	Hold	234	–	–	0.41%	49
2016 Q2	$3.56M	Buy	+234	New	+$5.35M	0.31%	67

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

CQS Cayman's TPST Position: Q1 2017 in Review

CQS Cayman sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 234 shares — an estimated $1.05M sold.

CQS Cayman first reported a position in TPST in Q2 2016 and held it in 3 quarters. The position peaked at $4.9M in Q3 2016. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

CQS Cayman reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
CQS Cayman sold 234 Tempest Therapeutics shares in Q1 2017, an estimated $1.05M.
CQS Cayman first reported a position in Tempest Therapeutics in Q2 2016 and held it in 3 quarters.
CQS Cayman's Tempest Therapeutics position peaked at $4.9M in Q3 2016.
63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on CQS Cayman's 13F filing for Q1 2017, filed 15 May 2017.